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Abstract
Background: Long-lasting insecticidal nets (LLINs) are currently the primary method of malaria control in sub-
Saharan Africa and have contributed to a significant reduction in malaria burden over the past 15 years. However,
this progress is threatened by the wide-scale selection of insecticide-resistant malaria vectors. It is, therefore,
important to accelerate the generation of evidence for new classes of LLINs.
Methods: This protocol presents a three-arm superiority, single-blinded, cluster randomized controlled trial to evaluate
the impact of 2 novel dual-active ingredient LLINs on epidemiological and entomological outcomes in Benin, a
malaria-endemic area with highly pyrethroid-resistant vector populations. The study arms consist of (i) Royal Guard®
LLIN, a net combining a pyrethroid (alpha-cypermethrin) plus an insect growth regulator (pyriproxyfen), which in the
adult female is known to disrupt reproduction and egg fertility; (ii) Interceptor G2® LLIN, a net incorporating two
adulticides (alpha-cypermethrin and chlorfenapyr) with different modes of action; and (iii) the control arm, Interceptor®
LLIN, a pyrethroid (alpha-cypermethrin) only LLIN. In all arms, one net for every 2 people will be distributed to each
household. Sixty clusters were identified and randomised 1:1:1 to each study arm. The primary outcome is malaria case
incidence measured over 24months through active case detection in a cohort of 25 children aged 6months to 10
years, randomly selected from each cluster. Secondary outcomes include 1) malaria infection prevalence (all ages) and
prevalence of moderate to severe anaemia in children under 5 years old, measured at 6 and 18months post-
intervention; 2) entomological indices measured every 3 months using human landing catches over 24months.
(Continued on next page)
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: manfred.accrombessi@lshtm.ac.uk
1Faculty of Infectious and Tropical Diseases, Disease Control Department,
London School of Hygiene and Tropical Medicine, WC1E 7HT, London, UK
Full list of author information is available at the end of the article
Accrombessi et al. BMC Infectious Diseases          (2021) 21:194 
https://doi.org/10.1186/s12879-021-05879-1
(Continued from previous page)
Insecticide resistance intensity will also be monitored over the study period.
Discussion: This study is the second cluster randomised controlled trial to evaluate the efficacy of these next-
generation LLINs to control malaria transmitted by insecticide-resistant mosquitoes. The results of this study
will form part of the WHO evidence-based review to support potential public health recommendations of
these nets and shape malaria control strategies of sub-Saharan Africa for the next decade.
Trial registration: ClinicalTrials.gov, NCT03931473, registered on 30 April 2019.
Keywords: Dual-active ingredient long-lasting insecticidal nets, Chlorfenapyr, pyriproxyfen, Royal Guard®,
Interceptor® G2, Malaria case incidence, Malaria prevalence, Entomological inoculation rate, Cluster randomized
controlled trial, Benin
Background
Insecticide-treated nets (ITNs) and, more recently, long-
lasting insecticidal nets (LLINs) are the most widely used
preventive measure for controlling malaria in sub-Saharan
Africa (SSA) [1]. The World Health Organization (WHO)
estimates that over 50% of the SSA population now sleep
under LLINs and together with improved diagnosis and
treatment, nets have contributed to an estimated 42 and
66% reduction in malaria incidence and mortality, respect-
ively, over the last 15 years [2]. Pyrethroids are currently
the only type of insecticide used routinely on LLINs, and
the rapid spread of pyrethroid-resistant vectors seriously
threatens to reverse the gains achieved so far [3]. Indeed,
several studies have demonstrated that LLINs are becom-
ing less effective at killing mosquitoes in areas of high
resistance compared to areas of susceptibility [4, 5], al-
though epidemiological evidence remains inconclusive in
some studies [6, 7].
Due to concerns about the potential failure of current
control tools as a result of insecticide resistance, WHO
has encouraged manufacturers to develop new types of
LLINs as part of the Global Plan for Insecticide Resistance
Management in malaria vectors (GPRIM) [8]. The first
nets to contain a mixture of active ingredients with evi-
dence for impact on epidemiological outcomes were nets
that combined a pyrethroid insecticide with the synergist
piperonyl butoxide (PBO) which restores susceptibility to
pyrethroid by neutralising mixed-function oxidase func-
tion responsible for resistance in vectors [9, 10].
New classes of ITNs combining two insecticides with dif-
fering modes of action could have the potential to improve
vector control and delay the evolution of resistance and pre-
serve the lifespan of both active ingredients (AI). The two
most advanced products are the pyrethroid-pyriproxyfen
LLIN (Olyset® Duo and Royal Guard®) [11–14] and a
pyrethroid-chlorfenapyr LLIN (Interceptor® G2) [15–17].
Both types of LLINs have demonstrated improved efficacy in
entomological studies but currently, limited epidemiological
evidence has been generated. Most of the available evidence
for these new nets are based on Phase I laboratory studies
and Phase II experimental hut trials. Only Olyset® Duo has
been tested in an randomized clinical trial (RCT) in Burkina
Faso and demonstrated efficacy on malaria case reduction in
comparison to clusters using standard pyrethroid nets [12].
There are currently no published data on the impact of
Royal Guard® and Interceptor® G2 on malaria epidemio-
logical outcomes. These LLINs need to be evaluated in
the community to determine the full extent of their effect-
iveness for malaria control. Failure to do so will – as
shown by the recent history of PBO LLINs [18, 19] – delay
the scale-up of new and potentially effective tools due to
lack of malaria control evidence. To receive a public
health recommendation from WHO, new types of LLIN
need to demonstrate improved epidemiological efficacy
compared to standard pyrethroid LLIN in two settings
[20]. A trial evaluating the same dual-AI LLINs is cur-
rently ongoing in Tanzania (clinical.gov, NCT03554616).
West Africa constitutes a different environment and ecol-
ogy from East Africa, with historically higher intensity of
pyrethroid resistance in malaria vectors [21] and so far
there is only limited entomological and epidemiological
evidence that new mixture nets would have a better effect
on malaria indicators compared to standard nets [14, 15].
The main objective of the present study is to assess the
efficacy of two types of dual-AI LLINs on malaria in a set-
ting where the main malaria vectors are resistant to pyr-
ethroid insecticides. Secondary objectives are to assess the
durability and bio-efficacy of the dual-AI LLINs in the
community [22]; and to examine whether entomological
outcomes from adapted experimental hut trials can pre-
dict epidemiological and transmission outcomes of the
RCT using a malaria transmission model developed by
Churcher et al. [23, 24]. The study protocol is reported in
line with the Standard Protocol Items: Recommendations




To evaluate the efficacy of two types of dual-AI LLINs
compared to standard pyrethroid LLINs on malaria case
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incidence in children aged 6 months to 10 years during
two years of follow up.
Secondary objectives
– To assess the efficacy of each dual-AI LLIN com-
pared to a standard pyrethroid-only LLIN on malaria
infection prevalence in all age groups, and preva-
lence of moderate to severe anaemia in children
under 5 years old, at 6 and 18 months post-net
distribution.
– To assess if dual-AI LLINs have a safety profile simi-
lar to pyrethroid-only LLINs in the population of
the trial study area.
– To monitor and evaluate the equity of study nets
coverage and usage in the trial.
Entomology
Primary objective
To assess the efficacy of each dual-AI LLINs compared
to a standard pyrethroid-only LLIN on mosquito density,
sporozoite rate, and the entomological inoculation rate
(EIR) as a measure for malaria transmission.
Secondary objectives
– To assess the impact of the new type of LLINs on
Anopheles vector survivorship and other
entomological outcomes (e.g., mosquito resting
behaviour, species composition, feeding, ovary
development, and fecundity).
– To assess annual changes in insecticide resistance
intensity to the three insecticides used on the nets.
Methods/design
Study area
The study site is situated in Cove, Zagnanado, and
Ouinhi Districts, located in the Zou department, central
Benin, 154 km north of Cotonou, the economic capital
(Fig. 1). The area was selected because of (i) a prevalence
of malaria infection between 20 to 40%, (ii) high pyreth-
roid resistance in the main malaria vectors, (iii) and
proximity to experimental hut sites. This area consists of
123 villages with approximately 54,000 households and
population size of 220,000 inhabitants. The main eco-
nomic activities of the population are farming, fishing,
hunting, and trading [26, 27].
Malaria is highly endemic, and transmission occurs
year-round. There are two rainy seasons, from April –
July and from October – November. Malaria infection
prevalence in the Zou department was 20% in children
under 5 years old according to the demographic health
survey (DHS) conducted in 2011–2012 [28] and in-
creased to 36.5% in the 2017–2018 DHS [29]. The main
vector control provision in the Zou department consists
of the distribution of pyrethroid-only LLINs through
regular universal coverage campaigns (most recently in
2017) and routine service delivery to pregnant women
during antenatal care and to children under 5 years dur-
ing extended programmes on immunization. According
to the 2018 DHS, ITN usage in children under 5 years
was 78.2%.
The main vector species are Anopheles coluzzii and
Anopheles gambiae sensu stricto. Entomological surveys
performed in the Cove region in 2015 revealed high
levels of pyrethroid resistance intensity (> 200 fold)
mainly due to high frequencies of kdr of > 90% and ele-
vated cytochrome P450 enzymes [30].
Trial design
The trial is a three-arm superiority, single-blinded,
cluster-randomized trial with 20 clusters in each arm (60
clusters in total). The 3 arms are (i) mixture pyrethroid
and chlorfenapyr LLIN: Interceptor® G2 (Intervention 1),
(ii) mixture pyrethroid-pyriproxyfen LLIN: Royal Guard®
(Intervention 2), (iii) pyrethroid-only standard LLIN:
Interceptor® (Control/reference arm). The study design
is summarized in Fig. 2.
Each cluster will be comprised of 1 village or a group
of villages for an average of 200 households (1200 resi-
dents) per cluster. Clusters will have a minimum of 100
children and 100 households. A “fried egg” design will
be used for cluster boundaries. Clusters will be designed
with core and buffer areas to reduce the likelihood of
spill-over of intervention effects. Nets will be distributed
to all households in a cluster (i.e. core and buffer areas)
but data collection to measure intervention effects will
be restricted to households situated in the core areas to
avoid spillover from neighbouring clusters receiving dif-
ferent nets. The cluster demarcation will be performed
using the spatial analyst toolbox in ArcGIS (ESRI, Red-
lands, USA) based on the following criteria; a minimum
of 50 children aged 6 months to 10 years in the core area
and a buffer of minimum 1000m between core house-
holds and any households in an adjacent cluster.
To estimate malaria case incidence, a cohort of 25
children per cluster aged 6 months to 9 years will be ran-
domly selected from a census list of children living in
the study clusters and followed over 24 months. For mal-
aria infection prevalence assessment, two cross-sectional
surveys will be conducted at 6 and 18months post-net
distribution; 70 individuals per cluster will be randomly
selected for each cross-sectional survey, stratified by age
(< 5 years, 5–9 years, 10–14 years, ≥15 years and older)
from each of the 60 clusters.
Routine cross-sectional entomological surveys using
human landing catches (HLCs) will be conducted in all
clusters to assess the human biting rate and EIR. Each
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cluster will be visited once every three months. Four
households will be selected from a census list in each
study cluster at each time point. The first house will be
randomly selected by the study data manager, while the
other three will be chosen by the field team, in a radius
of 15–20 m around the first one, to facilitate the supervi-
sion of mosquito collectors.
Eligibility criteria
The cohort will include children aged 6 months to 9
years old resident in the study villages, without any se-
vere illnesses and whose parents/carers have given writ-
ten informed consent for their child to be included in
the study. Inclusion criteria during cross-sectional sur-
veys will be the willingness to participate and provide
Fig. 1 Study area. Map showing Cove, Zagnanado and Ouinhi Districts, located in Zou department, central Benin, West Africa (Panel a); the 60 study
clusters identified with core and buffer area and intervention allocation (Panel b); a minimum of 1000m area was created between households in
adjacent clusters (Panel c). Source of map: Own from the study investigators (CT, JC, MA, ED).
Fig. 2 Summary of study design
Accrombessi et al. BMC Infectious Diseases          (2021) 21:194 Page 4 of 12
consent (or for parents/carers to provide consent for
children); resident in the village during the previous 3
months, selected individuals without severe illness.
Interventions
Description of the study nets
The nets are blue, rectangular, and identical sizes (1.8 m
long, 1.6 m wide, and 1.8 m high); however, the Royal
Guard® textile is different from the other two nets (de-
tails below). The three net brands are all WHO pre-
qualified vector control products [31].
Intervention 1: Interceptor® G2 (BASF Corporation) is
a mixture LLIN made of polyester netting (100 deniers)
coated with a wash-resistant formulation of 200 mg/m2
chlorfenapyr and 100 mg/m2 alpha-cypermethrin. Chlor-
fenapyr is a member of the pyrrole class of insecticides
[32] and disrupts cellular respiration and oxidative phos-
phorylation in mitochondria and due to this unique
mode of action is toxic to mosquitoes that are resistant
to standard neurotoxic insecticides like pyrethroids [33].
No record of cross-resistance to chlorfenapyr has been
reported up to now.
Intervention 2: Royal Guard® (Disease Control Tech-
nologies, LLC) is a mixture LLIN made of polyethylene
(120 deniers) incorporating 225 mg/m2 pyriproxyfen and
261 mg/m2 alpha-cypermethrin. Pyriproxyfen is a mul-
tiple acting compound (known as a juvenile hormone
analogue) with insecticidal and sterilising effects on fe-
males which is known to disrupt reproduction and fertil-
ity of eggs [34].
Control: Interceptor® LLIN (BASF Corporation) is a
pyrethroid-treated LLIN with alpha-cypermethrin (coated
onto filaments) at a target dose of 200mg/m2 of polyester
fabric (100 deniers). Interceptor was chosen as a direct
comparison to Interceptor G2 and Royal Guard as all
three nets are impregnated with alpha-cypermethrin pyr-
ethroid (albeit at different concentrations) and because
some pyrethroid resistance mechanisms involving CYP6
genes are specific to type I (permethrin) or type II (alpha-
cypermethrin) pyrethroids [35].
Intervention description
Nets will be distributed with the support of the National
Malaria Control Programme (NMCP). All households in
the study area will receive one net for every two people.
The census listing will be used to facilitate net distribu-
tion at a central location in each hamlet. To reach a
minimum of 85% access following the distribution and a
minimum of 75% usage, information, education, and
communication (IEC) activities will be conducted before,
during, and after LLIN distribution to increase usage in
the study area, including instructions on when and how
to wash the nets. A door to door hang-up campaign will
take place after the distribution and depending on net
usage rates, subsequent hang-up campaigns will be orga-
nized to increase net usage. Throughout the study, com-
munity health workers will be utilized to encourage
continuous net use in the study population. Hamlet and
religious leaders will be also involved in the sensitization
campaigns for net usage.
The coverage achieved in each cluster will be evalu-
ated through a post-intervention coverage survey one
month after distribution. Net coverage and usage will
also be assessed during cohort visits and cross-sectional
surveys. Three indicators will be used: “proportion of
households with at least one ITN for every 2 people”,
“proportion of household members with enough ITNs to
sleep under (population access)” and “proportion of resi-
dents reporting using an ITN last night” [36, 37].
Outcomes
The primary outcome is malaria case incidence in chil-
dren aged 6 months to 10 years (Table 1) over 24
months. A malaria case is defined as an infra-rouge
frontal temperature above 37.5 °C or history of a fever in
the last 48 h and a positive rapid diagnostic test (RDT).
Secondary outcomes are
– Malaria infection prevalence in the study population
at 6 and 18 months post bed net distribution,
– Prevalence of moderate to severe anaemia in
children under 5 years old at 6 and 18 months post
bed net distribution,
– EIR, as a measure for malaria transmission rate in
the primary vector species.
Other outcomes are:
– Mosquito density and survivorship, mosquito resting
behaviour, species composition, ovary development,
and fecundity.
– Frequency and intensity of phenotypic and
genotypic resistance to pyrethroid, chlorfenapyr, and
pyriproxyfen insecticides.
– Prevalence of elevated cytochromeP450s and other
metabolic enzymes associated with pyrethroid
resistance [38].
Sample size
Sample size calculation for the primary outcome (mal-
aria case incidence in children aged between 6months
and 10 years) was based on the method of Hayes and
Bennett [39]. Based on passive data collected in 2018 by
the NMCP in the study area, the mean number of mal-
aria episodes per child per year in the reference arm was
assumed to be 1. We assumed a between-cluster coeffi-
cient variation of 0.3 and that dual-AI LLINs will reduce
Accrombessi et al. BMC Infectious Diseases          (2021) 21:194 Page 5 of 12
malaria case incidence by 30% (i.e. to 0.7 cases per child
per year). With a follow-up of 2 years, to detect this ef-
fect size with 80% power would require following 20
children and 5 additional children to account for the loss
of follow-up (25 in total) in 20 clusters in each of the
three arms. This sample size calculation includes adjust-
ment for multiple testing (allowing for the 3 arms) using
a Bonferroni-corrected two-sided alpha of 1.67%. This
results in a total of 60 clusters required for the trial and
a cohort of 1500 children.
For the cross-sectional surveys, it was assumed that
malaria prevalence in the reference arm is 40%, with a
coefficient of variation between clusters of 0.3. With 70
individuals per cluster and 20 clusters per arm, the study
will have 80% power to detect a relative 30% lower
prevalence (prevalence ratio 0.70) between each inter-
vention arm to standard LLIN using a Bonferroni-
corrected two-sided alpha of 1.67% to account for mul-
tiple comparisons.
To achieve adequate participant enrolment to reach the
target sample size, enhanced community sensitization ac-
tivities will be conducted before and during each activity
in the community with the support of hamlet leaders and
community health workers.
Assignment of interventions: allocation and blinding
Restricted randomisation will be used to allocate the 60
clusters into the three study arms. Arms will be balanced
on the following criteria: population size of the cluster
(required to balance net numbers), infection prevalence,
and socio-economic status. Data on these variables by
cluster will be obtained through the pre-trial (baseline)
cross-sectional survey.
The study is a single-blinded trial. Study participants
will be blinded to the type of nets they have received. All
field staff will be blinded to the allocation and analyses
will be conducted on blinded data.
Data collection, management, and analysis
Census
A short questionnaire will be used to collect demo-
graphic details on household residents to estimate the
number of nets required to be distributed in each house
and to randomly select children for the cohort. Each
building will be mapped using a Global Positioning Sys-
tem to assist with delineating clusters.
Cohort monitoring
All children included in the cohort will be cleared of in-
fection at enrolment using directly observed treatment
with artemisinin-based combination therapy (ACT).
During follow-up, visits will take place every two weeks
during the malaria transmission season (from April to
November) and every month during the dry season
(from December to March). During each visit, children
with fever (temperature ≥ 37.5 °C) or reporting a fever in
the past 48 h will be tested for the presence of malaria
parasites using RDT (SD Bioline Malaria Ag P.f, HRP2,
Standard Diagnostics, Germany). If a child has a positive
Table 1 Study outcomes, measurements, and process of collection
Outcome Measurement Collection
Epidemiological outcomes
Malaria case incidence Rapid diagnostic test taken when temperature≥ 37.5 °C and/or history
of fever for the past 48 h
Active case detection: cohort follow-up
Malaria infection prevalence Rapid diagnostic test whatever the presence of malaria signs Cross-sectional survey
Moderate to severe anaemia Haemoglobin (measured by Haemocue), defined as < 10 g/dL and < 8 g/
dL, respectively.
Active case detection: cohort follow-up
Cross-sectional survey
Temperature Digital infra-red ear thermometer
Temperature and history of fever





Human landing catch Entomology monitoring
Mosquito sporozoite rate Standard CSP-ELISA uses to estimate the EIR. The positive sample will be




An. gambiae, An. coluzzii and An. funestus Taq Man Real time PCR Entomology monitoring
Sentinel site and resistance test
Resistance intensity WHO cylinder assay, collection of adult Anopheles resting indoor Entomology monitoring
Frequency of Vgsc mutation Taq Man PCR Entomology monitoring
Identification and intensity of
overexpressed CYP6 genes
Screening for CYP6 genes by using Microarrays
Reverse-transcription quantitative PCR (RT-qPCR) using for confirming
and monitoring the expression of the cytochrome identified
Resistance activity, unfed 3 days old
adult Anopheles from larval collection
Abbreviations: EIR Entomological inoculation rate
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RDT, they will be recorded as a malaria case and will re-
ceive treatment as per national guidelines [40].
During the enrolment visit, a detailed questionnaire
will be administered, to collect information on net own-
ership, household assets (as a proxy for socioeconomic
status) and housing materials and window screening,
and a clinical examination of the child will be con-
ducted. In follow-up visits, a short questionnaire will be
administered to record information on LLIN usage the
night before, any adverse events encountered, and travel
history. At each visit, children will also be examined by
study nurses for signs of other illnesses and will be
treated if needed. A child will be considered “lost to
follow-up” if they miss at least 4 consecutive visits (i.e. 8
weeks of follow-up time).
Cross-sectional surveys
Each survey will include two components; i) a household
survey and ii) a clinical survey. During the household
survey, a questionnaire will be administered to obtain in-
formation on demographic and socioeconomic data,
educational status, wealth assets of the household, vector
control measures, and randomly sampled persons (2 per
household) will be tested for malaria using an RDT, re-
gardless of symptoms. Haemoglobin level will be mea-
sured with an HemoCue device (HemoCue Hb 201+,
Aktiebolaget Leo Diagnostics, USA) in children under 5
who will receive iron tablets if they are found to be an-
aemic. Information will be collected on the perception
and acceptance of nets. The occurrence of adverse
events will also be reported.
Entomology activities
Entomological monitoring will take place every 3months
in each of the 60 study clusters. A standardized ques-
tionnaire will be used in each selected household to rec-
ord the number of inhabitants, type of house (wall, roof,
number of rooms, number of sleeping places), presence
of animals, and malaria prevention measures used by
household members. Mosquito collections will take
place using HLCs. Four trained volunteer mosquito col-
lectors from each study cluster will participate in house
collections; one will be seated indoors and the second
outdoors, and both will be replaced after 6 h of collec-
tion by the other two collectors. The collectors will be
supervised by a team leader during the collection night.
Mosquitoes collected will be identified by microscopy
and the numbers of An. gambiae s. l., An. funestus s. l.
and other anophelines recorded [41]. Human biting rate
(outdoor and indoor) will be compared between study
arms. Parity rates will be estimated in a subset of live
Anopheles mosquitoes through dissection of ovaries [42].
The presence of Plasmodium falciparum circumsporo-
zoite protein (Pf-CSP) in Anopheles vectors will be
identified in a sub-sample (minimum of 50 Anopheles
from indoor and outdoor collections per house) using an
enzyme-linked immunosorbent assay (ELISA) [43]. All
An. gambiae s.l. positive for Pf-CSP and a sub-sample of
negative specimens will be identified to species-level by
PCR [44]. The EIR will be calculated as the aggregated
mean of sporozoite infective bites/person/year. In order
to assess the impact of the pyrethroid-pyriproxyfen LLIN
(Royal Guard®) on mosquito reproduction, blood-fed
Anopheles will be collected and ovary development re-
corded each year in houses from study arms, by
dissection.
Insecticide resistance will be monitored annually using
standard CDC intensity bottle assays [45] in the three
arms to determine the prevalence of any selection of re-
sistance to pyriproxyfen or chlorfenapyr, or change in
resistance to pyrethroids. To monitor changes in insecti-
cide resistance, adult Anopheles will be tested in CDC
bottle bioassays using discriminating dosages of alpha-
cypermethrin (12.5 μg/ml), chlorfenapyr (100 μg/ml) and
pyriproxyfen (100 μg/ml) [46]; where mosquito mortality
is < 90% to alpha-cypermethrin, intensity assays, testing
two, five and ten times the discriminating dose will be
performed. The percentage mortality at 30 min and 24,
48, and 72 h post-exposure will be recorded. Mosquitoes
exposed to pyriproxyfen will be dissected to assess ovary
development [47]. Tests will be performed at baseline
and once per year post-intervention in two clusters per
study arm.
All knockdown/dead mosquitoes after insecticidal ex-
posure and surviving 72 h post-exposure to insecticides
will be stored individually in RNAlater® and preserved at
− 20 °C for gene expression analysis. Following species
identification by PCR, RNA will be extracted from pools
of confirmed An. gambiae s.s. or An. coluzzii and cDNA
synthesized, according to standard procedures. Relative
expression of CYPs and other metabolic enzymes, previ-
ously identified as being over-expressed in resistant An.
gambiae s.l. will be measured using multiplex TaqMan
RT-qPCR assays [48].
Data management
Household data, clinical measurements in the cohort
study, and entomological data collected during the
cross-sectional surveys will be captured in electronic
forms on smartphones installed with Open Data Kit
(ODK) collect. The data will be stored on a secure server
located at the London School of Hygiene and Tropical
Medicine (LSHTM) and all data management and ana-
lyses will be done using Stata software.
Data quality and control (QC)
Standard operating procedures (SOPs) for data collec-
tion will be developed and field study staff will be
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appropriately trained to ensure rigorous data collection.
QC will be conducted by a supervisor who will monitor
the performance of field staff by checking for complete-
ness and internal consistency of responses on the same
day as data collection. Data collected on paper forms
(mosquito identification, insecticide resistance results)
will be double entered into a database independently by
two data clerks. During the study, the data manager will
prepare regular QC reports to document the status of
data entry and any corrective actions needed.
Data security All data will be uploaded into a secure
server on the LSHTM cloud. Data will be stored
encrypted and will be accessible only by secure encryp-
tion keys and passwords. Access to the data will be re-
stricted only to authorised study investigators and data
management staff. A unique identifier number will be
given to each participant and household to safeguard
confidentiality.
Data storage Upon completion of the study, electronic
files will be stored on a server and also copied to
encrypted USB and stored offsite in a safe box. Case re-
port forms (CRFs) will be stored in the secure archive
equipped with locked cabinets for long-term storage. Elec-
tronic data and paper source records will be retained for a
minimum of 10 years following the study completion.
Statistical methods
Descriptive statistics will be used to compare the charac-
teristics of participants between the study arms. All pri-
mary analyses will be conducted by intention to treat
and adjusted for the restriction variables used for the
constrained randomisation.
Primary outcome To assess whether the new dual-AI
LLINs are superior to the reference LLIN, malaria case
incidence in each intervention arm (Royal Guard and
Interceptor G2) will be compared to malaria case inci-
dence in the reference arm (Interceptor). To adjust for
the increased risk of type I error due to multiple pair-
wise comparisons, the level of significance will be ad-
justed using the Bonferroni method. Following any
treatment for malaria, a child will not be considered at
risk for two weeks. Multilevel mixed models with ran-
dom effects will be used to test the difference in inci-
dence rate between each intervention and the control
arm, allowing for repeated measurements on the same
individual, and within-cluster correlation of responses.
Survival analyses will be also used to compare time to
the first infection case, adjusting for confounding factors
using a Cox proportional hazards model. Multiple events
will be allowed per child (with appropriate censoring to
account for prophylactic protection following treatment
and absence during follow-up visits).
Secondary outcomes Prevalence of malaria infection in
the study clusters will be estimated at baseline, 6
months, and 18 months. The surveys will be analysed
separately and in a combined model, controlling for the
time in the analyses. All analyses will account for the
multilevel nature of the data using random-effects re-
gression models. The prevalence of moderate and severe
anaemia in children under 5 will be analysed using logis-
tic regression.
EIR will be estimated as the mean number of sporozo-
ite infected Anopheles (An. gambiae s.I.) collected in the
HLCs per house per night and weighted to account for
the proportion of collected Anopheles processed for spo-
rozoites. Differences in Anopheles density and EIR be-
tween the different arms will be estimated using
random-effects negative binomial regression taking into
account the intra-cluster correlation and any confound-
ing factors that are found to be imbalanced between
arms. Random effects logistic regression will be used to
compare sporozoite rates between study arms allowing
for within cluster correlation of responses.
Oversight and monitoring
A Trial Steering Committee (TSC) and Data Safety and
Monitoring Committee (DSMC) will be established to
provide oversight for the study. The TSC and DSMC
members will be independent of the trial and its institu-
tions and have the necessary expertise to monitor study
progress and participant safety. The DSMC will be re-
sponsible for monitoring the progress of the trial, adher-
ence to the protocol, the safety data, and the critical
efficacy endpoints.
The management of the trial is the responsibility of
the chief investigator and co-investigators. They will en-
sure that data are recorded in compliance with good
clinical practice, and all regulatory and institutional
requirements.
Although the risk to study participants is considered
minimal from any of the study LLINs, their safety profile
will be documented. Any adverse events (AE) which
have been reported to be associated with exposure to in-
secticides such as skin rashes, skin burning, skin itching,
skin paraesthesia, watering eyes, runny nose, sneezing,
mucosal irritation, headache dizziness, and their severity
will be actively and passively monitored in the study co-
hort and study participants selected during the cross-
sectional survey. Serious adverse events (SAE) will be re-
ported to DSMC and ethical committees. Field workers
will be trained to handle any disclosure of personal in-
formation or health conditions reported sensitively and
confidentially.
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Ethics and dissemination
Research ethics approval
This study has been approved by the ethical review com-
mittee of the Ministry of Health in Benin (N°6/30/MS/
DC/DRFMT/CNERS/SA), the institutional review board
of London School of Hygiene and Tropical Medicine
(N°16,237), and the WHO Research Ethics Review Com-
mittee (ERC.0003153). Any amendments to the protocol
and informed consent forms will be submitted for ap-
proval to all three ethics committees. The trial is regis-
tered on clinicaltrials.gov (NCT03931473, registered on
30 April 2019).
The study will be conducted according to the Declar-
ation of Helsinki and the International Guidelines for
Ethical Review of Epidemiological Studies [49]. All field
and clinical staff as well as the investigators will receive
training on good clinical and laboratory practice before
data collection starts.
Informed consent procedure
Before any project activities, villages and hamlet leaders
and local health staff will be invited to sensitisation ses-
sions. Community health workers within each cluster will
be fully informed as to the aims of the trial and will be on
hand to answer day to day questions regarding the study.
For all activities involving a household, written in-
formed consent will be obtained from an adult guardian
in the household or be given by the participant if over
18 years. The consent form will be in French and indi-
cate the purpose of the study, procedures, risks, and
benefits. All participation is completely voluntary, and
participants can withdraw at any time. In case the par-
ticipant does not understand French, study investigators
will be trained to practice oral translation of the consent
into local languages. Participants will be asked to sign
the consent in duplicate, one will be kept by the project
and the other will remain with the household. If the per-
son consenting is unable to read or write, their finger-
print will be taken, and an impartial witness to the
informed consent procedures signature will be requested
to sign. For the active follow-up cohort, consent will be
sought once at the first enrolment visit and will be per-
formed by the study nurses. Assent will be sought for
children over 10 years.
For HLCs, written informed consent will also be ob-
tained from volunteer mosquito collectors before being
involved in the study. Mosquito collectors will be over
the age of 18 years. To prevent yellow fever, they will be
vaccinated. Their health will be monitored by the project
clinical team and free treatment for malaria will be pro-
vided, if necessary. Each volunteers will work one night
every 3 months to reduce the risk.
Confidentiality
All procedures for data collection, management, storage,
and manipulation will follow SOPs. To ensure confiden-
tiality is maintained, paper CRFs with participants’
names will be stored in a locked cabinet and only access-
ible by authorised staff. All analyses will be done using
the unique identifier.
Dissemination activities
All findings of the trial will be shared with international
policymakers such as the WHO Vector Control Advis-
ory Group (VCAG), the malaria policy advisory group
(MPAC), and the WHO prequalification team for vector
control product for revision of WHO guidance on dual-
AI LLINs. The project will involve the engagement of
national, local, and community authorities and leaders.
Mid- and end of project meetings will be organized to
share the progress with village and community leaders
to help disseminate findings to the community.
Discussion
A new generation of ITNs is urgently needed to main-
tain and ideally improve on the gains achieved by stand-
ard pyrethroid LLINs over the past two decades [18] and
to control malaria transmitted by pyrethroid-resistant
vectors. There is still only minimal evidence for the use
of these nets in areas of insecticide resistance [9, 10, 12],
and more evidence is required for consolidating the find-
ings of these initial trials.
The most advanced dual-AI LLIN assessed until now
are nets combining a synergist PBO and pyrethroid in-
secticide. Two large RCTs conducted in Tanzania [9]
and Uganda [10] have shown better efficacy than stand-
ard LLINs on malaria infection prevalence. This has led
to a recommendation from WHO that PBO nets can be
deployed across SSA in areas where vectors are resistant
to pyrethroid insecticides [50].
Pyriproxyfen-pyrethroids LLINs have shown improved
efficacy and wash resistance relative to pyrethroid-treated
nets in terms of mosquito mortality and prevention of
blood-feeding in experimental hut trials in Benin [11].
Several phase II studies conducted in West Africa have
also shown that this type of dual-AI LLIN had a significant
impact on mosquitoes’ fertility by sterilising a large pro-
portion of surviving blood-fed female mosquitoes through
the pyriproxyfen component [13, 14, 51]. To date, there is
only one RCT that assessed pyriproxyfen-pyrethroid
LLINs (Olyset® Duo). The trial was conducted in Burkina
Faso over 18months and showed 12% protective efficacy
compared to the standard net on malaria case incidence
but no reduction in infection prevalence [12]. The rela-
tively small protective effect could be due to the short re-
sidual bio-efficacy of pyriproxyfen on the net. Indeed, the
study investigators reported that fecundity indicators were
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only reduced in the first month after the use of the
pyriproxyfen-pyrethroid LLINs, but not thereafter [52].
Royal Guard®, also a dual pyriproxyfen-pyrethroid LLIN,
[14] induced greater levels of suppression of mosquito
reproduction in Phase I and II trials than that which was
reported in similar studies with Olyset® Duo [11].
Chlorfenapyr-pyrethroid LLINs have demonstrated better
efficacy and wash resistance against pyrethroid-resistant
mosquitos in comparison to standard alpha-cypermethrin
LLINs in Phase I and II trials [15–17].
Currently, there is less evidence for the performance
of dual-AI LLINs on epidemiological outcomes in West
African communities where vectors usually display much
higher levels of insecticide resistance intensity than those
observed in East Africa, raising the concern that they
might not be as effective in areas with intense insecticide
resistance. The present trial will therefore answer a crit-
ical question about the efficacy of the most promising
generation of LLINs in West Africa (except for PBO-
pyrethroid LLINs which were not included). It is the
only clinical trial in the area to assess mixtures of adulti-
cides with different modes of action (chlorfenapyr and
pyriproxyfen) with alpha-cypermethrin. The findings of
this trial together with those of a similar RCT conducted
in Tanzania will be reviewed by the WHO VCAG and
will contribute to the body of evidence to enable policy
recommendations. If these two first-in-class products
demonstrate superior efficacy to standard LLINs, they
will be the first recommended LLINs impregnated with
an insecticide class other than pyrethroids and PBO in
the last three decades and will pave the way for the de-
velopment of further LLINs. Any dual-AI LLIN that will
be developed subsequently and share the same mode of
actions would need to show non-inferiority against ento-
mological outcomes in Phase II experimental hut condi-
tions to be prequalified by WHO [53].
LLINs combining two insecticides of unrelated classes
may become a key component of future insecticide re-
sistance management by decreasing selection pressure
(genotypic and phenotypic) among vector populations.
While resistance monitoring in the proposed study is
not powered to be able to detect significant changes, the
trialling side by side of dual-AI LLINs and standard
LLINs may allow us to detect important trends. Further-
more, profiling of insecticide resistance in the local vec-
tor will provide valuable information on the condition of
deployment of these tools.
Both nets being tested contain a pyrethroid. The main
effect of pyrethroids is to enhance the barrier offered by
the netting material by killing and repelling mosquitoes
and reducing blood feeding. The second AI in the dual
LLINs cannot provide this level of individual protection.
Neither chlorfenapyr nor pyriproxyfen has repellent ef-
fects. The main impact of the partner AIs will be to kill
or sterilise mosquitoes that come into contact with the
insecticides, therefore reducing the overall mosquito
population. For both nets, the impact of these interven-
tions is expected to be maximal at the community level
when net usage is high. It will be therefore critical to
achieve high population coverage. Several enhanced
community sensitization activities and hang-up cam-
paigns will be organized before, during, and after the
LLIN distribution.
Nets have been one of the mainstays of vector control
for several decades, primarily due to their ease of use
and effectiveness. However, as anecdotal reports of their
reduced efficacy are reported [4, 5, 54], alongside evi-
dence that new nets provide better protection, there is a
danger that community willingness to use nets may
wane. It is vital that confidence is maintained in these
life-saving tools. If these new generations of LLINs are
effective at reducing malaria, this trial will provide vital
evidence to policy-makers and will enable stakeholders
to consider these dual-AI LLINs as alternative solutions
for malaria control in areas of insecticide resistance.
List of protocol version
Protocol version 4.0: 30/06/2019
Trial status
Baseline surveys are completed, and the cohort recruit-
ment is currently running. Due to the COVID-19 pan-
demic and the cases confirmed in Benin, the recruitment
of cohort children has been postponed from April to July
2020. Entomological collection using human landing
catches were also suspended and resumed at the end of
June. Laboratory work and hut trial work continued as
normal. This delay has led to the loss of 3 months of
data collection; therefore, the sample size has been
modified accordingly. With a follow-up of 21 months, 30
children instead of 25 per cluster would be required for
detecting the impact of the study nets. For mosquito col-
lection, each cluster will be visited seven times over the
21months follow-up period. The amendments have
been submitted to the different ethics committee. All
staff is using appropriate protective equipment and hand
sanitation measures.
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